Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMRX Stock Forecast 2026-2027
$13.41
Current Price
$4.22B
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AMRX Price Targets
+11.9%
To High Target of $15.00
+11.9%
To Median Target of $15.00
-3.1%
To Low Target of $13.00
AMRX Price Momentum
+3.3%
1 Week Change
+6.7%
1 Month Change
+62.3%
1 Year Change
+6.4%
Year-to-Date Change
-0.6%
From 52W High of $13.49
+100.6%
From 52W Low of $6.69
📊 TOP ANALYST CALLS
Did AMRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amneal Pharma is one of their latest high-conviction picks.
Latest AMRX Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, AMRX has a bullish consensus with a median price target of $15.00 (ranging from $13.00 to $15.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $13.41, the median forecast implies a 11.9% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Glen Santangelo at Barclays, projecting a 11.9% upside. Conversely, the most conservative target is provided by David Amsellem at Piper Sandler, suggesting a 3.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMRX Analyst Ratings
5
Buy
0
Hold
0
Sell
AMRX Price Target Range
Low
$13.00
Average
$15.00
High
$15.00
Current: $13.41
Latest AMRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $15.00 |
| Oct 31, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $13.00 |
| Sep 16, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $14.00 |
| Mar 3, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $11.00 |
| Feb 24, 2025 | JP Morgan | Chris Schott | Overweight | Upgrade | $12.00 |
| Nov 11, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $11.00 |
| Oct 2, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $12.00 |
| Sep 6, 2024 | JP Morgan | Chris Schott | Neutral | Upgrade | $9.00 |
| Aug 13, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $10.00 |
| Aug 12, 2024 | Truist Securities | Les Sulewski | Buy | Maintains | $10.00 |
| May 6, 2024 | Goldman Sachs | Nathan Rich | Buy | Maintains | $8.00 |
| May 6, 2024 | Truist Securities | Les Sulewski | Buy | Reiterates | $9.00 |
| Mar 21, 2024 | Piper Sandler | David Amsellem | Overweight | Maintains | $8.00 |
| Mar 4, 2024 | Goldman Sachs | Nathan Rich | Buy | Maintains | $6.25 |
| Jan 29, 2024 | Barclays | Balaji Prasad | Overweight | Maintains | $8.00 |
| Nov 8, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $7.00 |
| Sep 6, 2023 | Truist Securities | Gregory Fraser | Buy | Reiterates | $6.00 |
| Aug 7, 2023 | Piper Sandler | David Amsellem | Overweight | Maintains | $5.00 |
| Aug 7, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $6.00 |
| Aug 7, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $5.00 |
Amneal Pharmaceuticals Inc. (AMRX) Competitors
The following stocks are similar to Amneal Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amneal Pharmaceuticals Inc. (AMRX) Financial Data
Amneal Pharmaceuticals Inc. has a market capitalization of $4.22B with a P/E ratio of 1,341.0x. The company generates $2.93B in trailing twelve-month revenue with a 0.2% profit margin.
Revenue growth is +11.7% quarter-over-quarter, while maintaining an operating margin of +11.9% and return on equity of +106.7%.
Valuation Metrics
Market Cap
$4.22B
Enterprise Value
$6.77B
P/E Ratio
1,341.0x
PEG Ratio
-0.6x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+11.7%
Gross Margin
+34.9%
Operating Margin
+11.9%
Net Margin
+0.2%
EPS Growth
+11.7%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
2.1x
Debt/Equity
-24.4x
ROE
+106.7%
ROA
+6.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amneal Pharmaceuticals Inc. (AMRX) Business Model
About Amneal Pharmaceuticals Inc.
What They Do
Develops and distributes generic and specialty pharmaceuticals.
Business Model
The company generates revenue by developing, manufacturing, and distributing a wide range of generic and specialty pharmaceuticals. It focuses on providing cost-effective medication alternatives, allowing it to capture a significant share of the pharmaceutical market, especially in therapeutic areas like oncology and the central nervous system.
Additional Information
Amneal Pharmaceuticals has a diverse portfolio that includes prescription generic drugs and niche markets, which enhances its growth potential. As a key player in the global pharmaceutical industry, it strategically invests in areas influenced by healthcare regulations and advancements in medical treatments, positioning itself for long-term value in the financial markets.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8,300
CEO
Mr. Chirag K. Patel
Country
United States
IPO Year
2018
Website
www.amneal.comAmneal Pharmaceuticals Inc. (AMRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jan 15, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Amneal Pharmaceuticals, Inc. (AMRX) presented at the 44th Annual J.P. Morgan Healthcare Conference, indicating engagement with investors and stakeholders in the healthcare sector.
Why It Matters
Amneal Pharmaceuticals' presentation at a major healthcare conference signals potential developments in their pipeline, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks emphasizes its Rank system based on earnings estimates and revisions to identify promising stocks, while also monitoring trends in value, growth, and momentum.
Why It Matters
The emphasis on earnings estimates and revisions can signal potential stock performance, guiding investors toward high-potential stocks amid evolving market trends.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
KeifeRx has partnered with Amneal Pharmaceuticals to advance KFRX06, a preclinical candidate targeting LRRK2 for Parkinson's disease, supporting its pre-IND development phase.
Why It Matters
KeifeRx's collaboration with Amneal Pharmaceuticals highlights potential breakthroughs in Parkinson's treatment, which may enhance investor confidence and increase market interest in biotech innovations.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Amneal Pharmaceuticals received FDA approval for two biosimilars: Boncresa™ (denosumab-mobz) referencing Prolia® and Oziltus™ (denosumab-mobz) referencing XGEVA®.
Why It Matters
FDA approval of Amneal's biosimilars Boncresa™ and Oziltus™ expands its product offerings, potentially increasing revenue and market share, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Amneal's buy rating is reaffirmed due to a strong drug portfolio and increased FY25 operating cash flow guidance, despite some technical signals suggesting a hold.
Why It Matters
Amneal's reaffirmed buy rating, strong drug portfolio growth, and increased cash flow guidance signal potential upside, making it an attractive opportunity despite current equity concerns.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Amneal Pharmaceuticals announced FDA approval for its epinephrine injection USP in both single-dose and multi-dose vials, essential for acute care facilities.
Why It Matters
FDA approval of Amneal's epinephrine injection enhances its product portfolio, potentially boosting revenue and market share in acute care, influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AMRX Stock
What is Amneal Pharmaceuticals Inc.'s (AMRX) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Amneal Pharmaceuticals Inc. (AMRX) has a median price target of $15.00. The highest price target is $15.00 and the lowest is $13.00.
Is AMRX stock a good investment in 2026?
According to current analyst ratings, AMRX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMRX stock?
Wall Street analysts predict AMRX stock could reach $15.00 in the next 12 months. This represents a 11.9% increase from the current price of $13.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amneal Pharmaceuticals Inc.'s business model?
The company generates revenue by developing, manufacturing, and distributing a wide range of generic and specialty pharmaceuticals. It focuses on providing cost-effective medication alternatives, allowing it to capture a significant share of the pharmaceutical market, especially in therapeutic areas like oncology and the central nervous system.
What is the highest forecasted price for AMRX Amneal Pharmaceuticals Inc.?
The highest price target for AMRX is $15.00 from Glen Santangelo at Barclays, which represents a 11.9% increase from the current price of $13.41.
What is the lowest forecasted price for AMRX Amneal Pharmaceuticals Inc.?
The lowest price target for AMRX is $13.00 from David Amsellem at Piper Sandler, which represents a -3.1% decrease from the current price of $13.41.
What is the overall AMRX consensus from analysts for Amneal Pharmaceuticals Inc.?
The overall analyst consensus for AMRX is bullish. Out of 13 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are AMRX stock price projections?
Stock price projections, including those for Amneal Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 5:52 AM UTC